Genetic ancestry plays a key role in determining the behavior of head and neck tumors and may help explain why ...

A recent retrospective study identifies key factors contributing to high failure rates of clinical trials evaluating treatments for head and neck squamous cell carcinoma.

The trial evaluates survival outcomes for recurrent head and neck squamous cell carcinoma post-radiation therapy, comparing surgery alone to neoadjuvant chemotherapy with or without immunotherapy.

Esophageal cancer occurring in patients with head and neck squamous cell carcinoma (HNSCC) represents a critical clinical challenge, as these secondary tumours notably worsen patient prognosis. Owing ...

Ancestry-specific biomarkers, such as POLB, could reshape diagnostic and prognostic approaches in head and neck cancer. New ...

Patients with head and neck squamous cell carcinoma can talk to their care team about a trial evaluating petosemtamab for recurrent or metastatic disease. The first patient has been dosed in a phase 3 ...

A new strategy that combines two types of PET scans can guide personalized radiotherapy for head and neck cancers, according ...

German biotech BioNTech today announced that the US Food and Drug Administration (FDA) has granted fast track designation to ...

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the breakthrough approval comes ...

Cleveland Clinic researchers have discovered that bacteria inside cancerous tumors may be key to understanding why immunotherapy works for some patients but not others. Subscribe to our newsletter for ...